Skip to main content
Top
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Clinicopathologic significance of HIF-1α, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer

Authors: Sung Yong Oh, Hyuk-Chan Kwon, Sung-Hyun Kim, Jin Seok Jang, Min Chan Kim, Kyeong Hee Kim, Jin-Yeong Han, Chung Ock Kim, Su-Jin Kim, Jin-sook Jeong, Hyo-Jin Kim

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Hypoxia influences tumor growth by inducing angiogenesis and genetic alterations. Hypoxia-inducible factor 1α (HIF-1α), p53, and vascular endothelial growth factor (VEGF) are all important factors in the mechanisms inherent to tumor progression. In this work, we have investigated the clinicopathologic significance of HIF-1α, p53, and VEGF expression and preoperative serum VEGF (sVEGF) level in gastric cancer.
We immunohistochemically assessed the HIF-1α, p53, and VEGF expression patterns in 114 specimens of gastric cancer. Additionally, we determined the levels of preoperative serum VEGF (sVEGF).

Results

The positive rates of p53 and HIF-1α (diffuse, deep, intravascular pattern) were 38.6% and 15.8%, respectively. The VEGF overexpression rate was 57.9%. p53 and HIF-1α were correlated positively with the depth of invasion (P = 0.015, P = 0.001, respectively). Preoperative sVEGF and p53 levels were correlated significantly with lymph node involvement (P = 0.010, P = 0.040, respectively). VEGF overexpression was more frequently observed in the old age group (≥ 60 years old) and the intestinal type (P = 0.013, P = 0.014, respectively). However, correlations between preoperative sVEGF level and tissue HIF-1α, VEGF, and p53 were not observed. The median follow-up duration after operation was 24.5 months. HIF-1α was observed to be a poor prognostic factor of disease recurrence or progression (P = 0.002).

Conclusion

p53, HIF-1α and preoperative sVEGF might be markers of depth of invasion or lymph node involvement. HIF-1α expression was a poor prognostic factor of disease recurrence or progression in patients with gastric cancers.
Appendix
Available only for authorised users
Literature
1.
go back to reference Liao D, Johnson RS: Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007, 26 (2): 281-290. 10.1007/s10555-007-9066-y.CrossRefPubMed Liao D, Johnson RS: Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007, 26 (2): 281-290. 10.1007/s10555-007-9066-y.CrossRefPubMed
2.
go back to reference Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 1997, 94 (15): 8104-8109. 10.1073/pnas.94.15.8104.CrossRefPubMedPubMedCentral Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 1997, 94 (15): 8104-8109. 10.1073/pnas.94.15.8104.CrossRefPubMedPubMedCentral
3.
go back to reference Wenger RH, Camenisch G, Desbaillets I, Chilov D, Gassmann M: Up-regulation of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction. Cancer Res. 1998, 58 (24): 5678-5680.PubMed Wenger RH, Camenisch G, Desbaillets I, Chilov D, Gassmann M: Up-regulation of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction. Cancer Res. 1998, 58 (24): 5678-5680.PubMed
4.
go back to reference Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, Laderoute K, Johnson RS: Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol. 2001, 21 (10): 3436-3444. 10.1128/MCB.21.10.3436-3444.2001.CrossRefPubMedPubMedCentral Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, Laderoute K, Johnson RS: Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol. 2001, 21 (10): 3436-3444. 10.1128/MCB.21.10.3436-3444.2001.CrossRefPubMedPubMedCentral
5.
go back to reference Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H, Kawamura K, Hosokawa M, Asaka M: Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 2001, 61 (17): 6548-6554.PubMed Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H, Kawamura K, Hosokawa M, Asaka M: Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 2001, 61 (17): 6548-6554.PubMed
6.
go back to reference Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ, Giaccia AJ: Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol. 1994, 14 (9): 6264-6277.CrossRefPubMedPubMedCentral Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ, Giaccia AJ: Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol. 1994, 14 (9): 6264-6277.CrossRefPubMedPubMedCentral
7.
go back to reference Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996, 379 (6560): 88-91. 10.1038/379088a0.CrossRefPubMed Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996, 379 (6560): 88-91. 10.1038/379088a0.CrossRefPubMed
8.
go back to reference Baas IO, Hruban RH, Offerhaus GJ: Clinical applications of detecting dysfunctional p53 tumor suppressor protein. Histol Histopathol. 1999, 14 (1): 279-284.PubMed Baas IO, Hruban RH, Offerhaus GJ: Clinical applications of detecting dysfunctional p53 tumor suppressor protein. Histol Histopathol. 1999, 14 (1): 279-284.PubMed
9.
go back to reference Frederick LG: Stomach. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 2002, Philadelphia: Lippincott-Raven, 99-106. 6 Frederick LG: Stomach. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 2002, Philadelphia: Lippincott-Raven, 99-106. 6
10.
go back to reference Roskoski R: Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 2007, 62 (3): 179-213. 10.1016/j.critrevonc.2007.01.006.CrossRefPubMed Roskoski R: Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 2007, 62 (3): 179-213. 10.1016/j.critrevonc.2007.01.006.CrossRefPubMed
11.
go back to reference Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL: Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 2000, 88 (11): 2606-2618. 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W.CrossRefPubMed Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL: Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 2000, 88 (11): 2606-2618. 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W.CrossRefPubMed
12.
go back to reference Theodoropoulos VE, Lazaris A, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, Manikas K, Kastriotis I: Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol. 2004, 46 (2): 200-208. 10.1016/j.eururo.2004.04.008.CrossRefPubMed Theodoropoulos VE, Lazaris A, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, Manikas K, Kastriotis I: Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol. 2004, 46 (2): 200-208. 10.1016/j.eururo.2004.04.008.CrossRefPubMed
13.
go back to reference Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, Wall van der E: Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 2001, 93 (4): 309-314. 10.1093/jnci/93.4.309.CrossRefPubMed Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, Wall van der E: Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 2001, 93 (4): 309-314. 10.1093/jnci/93.4.309.CrossRefPubMed
14.
go back to reference Kuwai T, Kitadai Y, Tanaka S, Onogawa S, Matsutani N, Kaio E, Ito M, Chayama K: Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer. 2003, 105 (2): 176-181. 10.1002/ijc.11068.CrossRefPubMed Kuwai T, Kitadai Y, Tanaka S, Onogawa S, Matsutani N, Kaio E, Ito M, Chayama K: Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer. 2003, 105 (2): 176-181. 10.1002/ijc.11068.CrossRefPubMed
15.
go back to reference Nakayama K, Kanzaki A, Hata K, Katabuchi H, Okamura H, Miyazaki K, Fukumoto M, Takebayashi Y: Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett. 2002, 176 (2): 215-223. 10.1016/S0304-3835(01)00762-5.CrossRefPubMed Nakayama K, Kanzaki A, Hata K, Katabuchi H, Okamura H, Miyazaki K, Fukumoto M, Takebayashi Y: Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett. 2002, 176 (2): 215-223. 10.1016/S0304-3835(01)00762-5.CrossRefPubMed
16.
go back to reference Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jurgensen JS, Gruber G, Maxwell PH, Loning SA, et al: Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res. 2001, 61 (13): 5215-5222.PubMed Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jurgensen JS, Gruber G, Maxwell PH, Loning SA, et al: Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res. 2001, 61 (13): 5215-5222.PubMed
17.
go back to reference Saramaki OR, Savinainen KJ, Nupponen NN, Bratt O, Visakorpi T: Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer. Cancer Genet Cytogenet. 2001, 128 (1): 31-34. 10.1016/S0165-4608(01)00396-X.CrossRefPubMed Saramaki OR, Savinainen KJ, Nupponen NN, Bratt O, Visakorpi T: Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer. Cancer Genet Cytogenet. 2001, 128 (1): 31-34. 10.1016/S0165-4608(01)00396-X.CrossRefPubMed
18.
go back to reference Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL: Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001, 61 (7): 2911-2916.PubMed Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL: Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001, 61 (7): 2911-2916.PubMed
19.
go back to reference Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G: Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res. 2001, 7 (6): 1661-1668.PubMed Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G: Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res. 2001, 7 (6): 1661-1668.PubMed
20.
go back to reference Hashimoto H, Akimoto M, Maeda A, Shigemoto M, Yamashito K: Relation of Hypoxia-Inducible Factor-1alpha to Vascular Endothelial Growth Factor and Vasoactive Factors During Healing of Gastric Ulcers. J Cardiovasc Pharmacol. 2004, 44: S407-S409. 10.1097/01.fjc.0000166305.79055.ad.CrossRefPubMed Hashimoto H, Akimoto M, Maeda A, Shigemoto M, Yamashito K: Relation of Hypoxia-Inducible Factor-1alpha to Vascular Endothelial Growth Factor and Vasoactive Factors During Healing of Gastric Ulcers. J Cardiovasc Pharmacol. 2004, 44: S407-S409. 10.1097/01.fjc.0000166305.79055.ad.CrossRefPubMed
21.
go back to reference Fondevila C, Metges JP, Fuster J, Grau JJ, Palacin A, Castells A, Volant A, Pera M: p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer. 2004, 90 (1): 206-215. 10.1038/sj.bjc.6601455.CrossRefPubMedPubMedCentral Fondevila C, Metges JP, Fuster J, Grau JJ, Palacin A, Castells A, Volant A, Pera M: p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer. 2004, 90 (1): 206-215. 10.1038/sj.bjc.6601455.CrossRefPubMedPubMedCentral
22.
go back to reference Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N, Ito H: Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer. 1997, 79 (11): 2067-2072. 10.1002/(SICI)1097-0142(19970601)79:11<2067::AID-CNCR3>3.0.CO;2-M.CrossRefPubMed Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N, Ito H: Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer. 1997, 79 (11): 2067-2072. 10.1002/(SICI)1097-0142(19970601)79:11<2067::AID-CNCR3>3.0.CO;2-M.CrossRefPubMed
23.
go back to reference Poon RT, Fan ST, Wong J: Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001, 19 (4): 1207-1225.PubMed Poon RT, Fan ST, Wong J: Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001, 19 (4): 1207-1225.PubMed
24.
go back to reference Baba M, Konno H, Maruo Y, Tanaka T, Kanai T, Matsumoto K, Matsuura M, Nishino N, Maruyama K, Nakamura S, et al: Relationship of p53 and vascular endothelial growth factor expression of clinicopathological factors in human scirrhous gastric cancer. Eur Surg Res. 1998, 30 (2): 130-137. 10.1159/000008568.CrossRefPubMed Baba M, Konno H, Maruo Y, Tanaka T, Kanai T, Matsumoto K, Matsuura M, Nishino N, Maruyama K, Nakamura S, et al: Relationship of p53 and vascular endothelial growth factor expression of clinicopathological factors in human scirrhous gastric cancer. Eur Surg Res. 1998, 30 (2): 130-137. 10.1159/000008568.CrossRefPubMed
25.
go back to reference Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996, 77 (5): 858-863. 10.1002/(SICI)1097-0142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A.CrossRefPubMed Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996, 77 (5): 858-863. 10.1002/(SICI)1097-0142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A.CrossRefPubMed
26.
go back to reference Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T: Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol. 1997, 15 (2): 826-832.PubMed Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T: Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol. 1997, 15 (2): 826-832.PubMed
27.
go back to reference Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, Xie K: Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res. 2004, 10 (12 Pt 1): 4109-4117. 10.1158/1078-0432.CCR-03-0628.CrossRefPubMed Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, Xie K: Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res. 2004, 10 (12 Pt 1): 4109-4117. 10.1158/1078-0432.CCR-03-0628.CrossRefPubMed
28.
go back to reference Konno H, Ohta M, Baba M, Suzuki S, Nakamura S: The role of circulating IL-8 and VEGF protein in the progression of gastric cancer. Cancer Sci. 2003, 94 (8): 735-740. 10.1111/j.1349-7006.2003.tb01511.x.CrossRefPubMed Konno H, Ohta M, Baba M, Suzuki S, Nakamura S: The role of circulating IL-8 and VEGF protein in the progression of gastric cancer. Cancer Sci. 2003, 94 (8): 735-740. 10.1111/j.1349-7006.2003.tb01511.x.CrossRefPubMed
29.
go back to reference Ohta M, Konno H, Tanaka T, Baba M, Kamiya K, Syouji T, Kondoh K, Watanabe M, Terada H, Nakamura S: The significance of circulating vascular endothelial growth factor (VEGF) protein in gastric cancer. Cancer Lett. 2003, 192 (2): 215-225. 10.1016/0304-3835(02)00681-X.CrossRefPubMed Ohta M, Konno H, Tanaka T, Baba M, Kamiya K, Syouji T, Kondoh K, Watanabe M, Terada H, Nakamura S: The significance of circulating vascular endothelial growth factor (VEGF) protein in gastric cancer. Cancer Lett. 2003, 192 (2): 215-225. 10.1016/0304-3835(02)00681-X.CrossRefPubMed
30.
go back to reference Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Ryu KW, Bae JM, Kim S: Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer. 2003, 39 (2): 184-191. 10.1016/S0959-8049(02)00596-8.CrossRefPubMed Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Ryu KW, Bae JM, Kim S: Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer. 2003, 39 (2): 184-191. 10.1016/S0959-8049(02)00596-8.CrossRefPubMed
31.
go back to reference Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, Karatzas G: Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg. 2002, 236 (1): 37-42. 10.1097/00000658-200207000-00007.CrossRefPubMedPubMedCentral Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, Karatzas G: Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg. 2002, 236 (1): 37-42. 10.1097/00000658-200207000-00007.CrossRefPubMedPubMedCentral
Metadata
Title
Clinicopathologic significance of HIF-1α, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer
Authors
Sung Yong Oh
Hyuk-Chan Kwon
Sung-Hyun Kim
Jin Seok Jang
Min Chan Kim
Kyeong Hee Kim
Jin-Yeong Han
Chung Ock Kim
Su-Jin Kim
Jin-sook Jeong
Hyo-Jin Kim
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-123

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine